Cardiac - ACS Flashcards

1
Q

Differentiate Unstable Angina, NSTEMI and STEMI

A

□ Unstable angina (UA): severe ischaemia at rest without infarction

□ NSTEMI: partial occlusion of coronary arteries (usually due to critical narrowing) → some myocardial necrosis but not transmural

□ STEMI: complete occlusion of coronary arteries (usually due to acute plaque disruption leading to complete thrombosis) → transmural myocardial necrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

4 major clinical presentations of ACS

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Acute MI Pathophysiology
Phases of myocardial response to AMI

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Causes of exertional chest pain vs resting chest pain

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Classification of ACS

A
  1. Unstable angina
    - Plaque rupture with thombus formation > partial occlusion of vessel with No infarction
  2. NSTEMI
    - Plaque rupture with thrombus formation > partial occlusion of vessel > subendocardial myocardial injury and infarct
  3. STEMI
    - Plaque rupture with thrombus formation > complete occlusion of 1 of 3 major coronary arteries > Transmural myocardial injury and infarct
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Outline diagnostic criteria for ACS (4)

A
  1. Clinical presentation
  2. ECG: Acute ischemic changes
  3. Biochemical: Biomarkers for myocardial injury

+/- 4. Imaging: ECHO or CT coronary angiogram show regional wall motion abnormality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the 4 types of chest pain in ACS

A

Clinical presentation: can be a new phenomenon or on top of background stable angina

Angina at rest: prolonged >20min angina at rest (due to accumulation of toxic metabolites)

New-onset angina: transient ectopic beats, pain

□ Increasing angina: previous angina w/ ↑frequency, ↑duration

Post-infarct angina: recurrent angina after recent MI

(complete infarct and totally ischemic muscles do not produce toxic metabolites that cause rest pain anymore)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Differentiate ACS and MI

A

ACS = clinical term referring to patients with suspicion or confirmation of acute myocardial ischaemia or infarction

MI = acute myocardial injury (as evidenced by ↑cTn) in the setting of clinical evidence of acute myocardial ischaemia (as evidenced by chest pain or ECG changes)

MI = all tests done and confirmed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ACS

Clinical presentation
Associated symptoms

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Risk factors of ACS
Triggering factors of ACS

A

Triggers:
□ Unusual heavy exercise
□ Emotional stress
□ Progression from Unstable Angina
□ Surgical procedures
Infections, eg. pneumonia
Circadian (peak incidence between 6am to 12pm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Ddx cardiovacular cause of chest pain

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ddx of respiratory cause of acute chest pain

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ddx of gastro-intestinal cause of acute chest pain

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Misc. ddx of chest pain

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Compare the different acute chest pain due to cardiac causes

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AMI

Investigations

A

Radiological Ix:
- ECG
- Echocardiogram: Regional wall motion abnormality, LVEF, complications such as MR/ VSD/ Pericardial effusion, Stress echo
- Coronary angioraphy: IVCA/ CTCA/ MRCA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

AMI ECG

Areas of infarction seen on ECG

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ECG features of NSTEMI

A

Non-ST-elevation ACS (NSTE-ACS):
□ Indicates: partial occlusion of major vessels(or complete occlusion of minor vessels) → unstable angina or subendocardial MI

ECG features:
→ ST depression
→ T wave changes
→ ± some loss of R waves (if infarcted)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Ddx ST elevation on ECG

A
  • Acute STEMI (Convex ST, III>II)
  • Acute pericarditis (Concave ST, II>I/III/aVF)
  • LVH with strain pattern (Concave ST, V1-2)
  • Early repolarization (J point elevation follows S wave, Concave ST, No reciprocal ST depression)
  • LBBB
  • Ventricular aneurysm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Other ECG features suggestive of acute MI other than ST segment changes

Changes in ECG findings after AMI

A

Hyperacute T wave: occurs within minutes of acute MI

Pseudonormalization of T wave: transient normalization of T wave from an inverted form (transient recanalization of coronary artery)

Wellens syndrome:** deeply inverted or biphasic T waves in V2-3** (High LAD stenosis)

ST elevation in aVR: usually indicates left main stem occlusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

List serum cardiac markers

Function of markers

A

Biomarkers:
* Myoglobin
* CKMB
* Cardiac Troponin I
* Cardiac Troponin T
* BNP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Compare the time course of each serum cardiac biomarker

A

1st: Myoglobin

2nd: Creatine kinase MB isoform (CKMB):
Course: rise (4-6h) → peak (12h) → normalize (48-72h)

3rd: Cardiac troponin T or I (cTnT, cTnI):
Course: rise (4-6h) → elevated for up to 2 weeks

Creatinine kinase - muscles, non-specific

Troponin - specific for cardiomyocyte, very sensitive (may have false positive)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Compare the function of Cardiac troponin T or I vs CKMB monitoring

A

Cardiac Troponin:

□ Advantages: not normally present → ↑sensitivity ↑specificity
□ Use: detection of first infarct event

CKMB:

□ Caveat: not sensitive or specific
(esp consider skeletal muscle damage eg. IM injection)
□ Use: mainly to detect early re-stenosis

24
Q

5 types of MI

A

Type 1: MI caused by Atherothrombotic CAD, preciputated by Atherosclerotic plaque disruption (rupture or erosion)

Type 2: MI secondary to ischemia due to imbalance between oxygen demand and supply (no atherothrombosis) eg. coronary spasm, anaemia or hypotension

Type 3: Sudden cardiac death - MI with typical symptoms and new ischemic ECG changes, but died before blood biomarker diagnosis

Type 4: MI related to PCI (procedural complication)

Type 5: MI related to CABG (procedural complication)

25
Investigations to confirm type 4 and 5 MI
1. New ECG changes 2. Angiography: evidence of new coronary artery occlusion 3. Imaging: evidence of new loss of regional wall movement/ new coronary artery occlusion/ loss of viable myocardium 4. Cardiac biomarkers >99 percentile URL
26
AMI Diagnostic criteria
27
Diagnostic criteria of type II MI
Detection of ↑/↓cardiac biomarker values (preferably cTn) with ≥1 value above 99th URL; plus ≥1 of 1. Symptoms of ischaemia 2. New or presumed new significant ST-T changes or new LBBB 3. Development of pathological Q waves 4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality **Same as Type 1 criteria but NO EVIDENCE OF CORONARY ATHEROTHROMBOSIS**
28
List some causes of Type II MI
Type 1 = atherosclerosis + thrombus; Type 2 = oxygen supply and demand mismatch, no thrombus Causes of increased coronary oxygen demand in type 2: 1. Coronary spasm 2. Coronary microvascular dysfunction 3. Coronary embolism 4. Coronary artery dissection 5. Severe HTN and LVH 6. Respiratory failure, severe anaemia, hypotension, shock
29
Outline the ddx if troponin levels rise/ fall vs stabilize over time
30
Indication for cardiac imaging Types of cardiac imaging
Indication: in patients with low-to-intermediate risk for ACS to rule out ACS Types: - Echocardiography - CT coronary angiogram - Stress imaging: ETT, MPI, stress echo/MRI
31
Outline the TIMI risk score for NSTE-ACS stratification
Early risk assessment for UA/ NSTEMI o All patients with UA/ NSTEMI should undergo risk assessment since it can determine prognosis and guide the timing of coronary angiography and possible revascularization o Early risk stratification tools = TIMI/ GRACE risk score
32
Outline the GRACE risk score scheme for NSTE-ACS stratification
Early risk assessment for UA/ NSTEMI o All patients with UA/ NSTEMI should undergo risk assessment since it can determine prognosis and guide the timing of coronary angiography and possible revascularization o Early risk stratification tools = TIMI/ GRACE risk score
33
Right coronary artery Origin Branches Supply territory Areas of corresponding infarct
34
Left coronary artery Origin Branches Supply territory Areas of corresponding infarct
35
Troponin Sources Limit for MI Confounding non-MI causes
Source: - Myocardial - Skeletal muscles cTn reference decision limit for MI - Any troponin elevation > 99th percentile (URL) = myocardial damage cTnT and cTnI - Sensitive and specific - Cardiac specific but NOT specific for the cause
36
Creatine kinase Sources Isoenzymes Function Confounding factors
37
5 principles of management of ACS Outline treatment plan
General management: - ABC, bed rest with continuous ECG monitoring - Support: Analgesics with morphine, Anxiolytics - First line investigations Acute: - Anti-thrombotic therapy: Anti-platelet + Anti-coagulants - Anti-ischmeic therapy: BB, CCB, Nitrates - Support: Analgesics with morphine, Anxiolytics - Coronary revascularization with fibrinolysis: tPA, rPA, Streptokinase - Coronary revascularization with PCI Long-term therapy and secondary prevention: - Lifelong aspirin +/- warfarin - ACEi/ARB - Aldosterone antagonist - Beta-blockers - Statin - Lifestyle modification
38
Anti-thrombotic therapy for ACS Drug choices MoA
Aspirin - Non-selective COX-1 and COX-2 inhibitors - ↓ Thromboxane A2 (TXA2) production from COX-1 by platelets - Inhibits platelet aggregation Thienopyridine (P2Y12) antagonist - P2Y12 is a component of ADP receptor - ADP is stored in platelet dense granules and released upon platelet activation - Amplifies the initial signal for platelet activation and facilitate platelet aggregation GP IIb/IIIa antagonist - bind to the receptor and prevent fibrinogen and von Willebrand factor (vWF) from binding to the receptors - protection from ischemic events in patients undergoing percutaneous coronary intervention (PCI)
39
Thienopyridine (P2Y12) antagonist Choice of P2Y12 antagonist Use with PCI, fibrinolysis or without fibrinolysis/PCI
40
GP IIb/IIIa antagonist Drug choice Benefit Contraindications
GP IIb/IIIa antagonist - bind to the receptor and prevent fibrinogen and von Willebrand factor (vWF) from binding to the receptors - protection from ischemic events in patients undergoing percutaneous coronary intervention (PCI)
41
Anti-coagulant for ACS Drug choice MoA S/E
42
Anti-coagulant for ACS Advantage of unfractionated heparin vs LMW heparin
43
Anti-ischemic therapy for ACS Drug choices Indications for each drug Contraindication MoA
44
ACS Supportive medication (apart from anti-thrombotic and anti-ischemic therapy)
45
Coronary revascularization via fibrinolytic therapy - Indications - MoA - Drug choices - Major complication
46
Coronary revascularization via fibrinolytic therapy Absolute contraindications Relative contrainfications
47
Coronary revascularization via PCI Indications in STEMI Access Stent choices Subsequent therapy
48
PCI Complications
49
ACS Signs of successful reperfusion
50
Factors indicating early invasive strategy or ischemia-guided strategy in NSTE-ACS
51
STEMI treatment flowchart
52
STEMI PCI choice flowchart
53
Long-term post-MI management
54
Structural and conductive complications of AMI
55
Circulatory complications of AMI